Navigating Psychological and Pharmacological Treatments for Disruptive DisordersNavigating Psychological and Pharmacological Treatments for Disruptive Disorders

PsycCRITIQUES ◽  
2016 ◽  
Vol 6161 (1313) ◽  
Author(s):  
Meera Rastogi
Keyword(s):  
Pharmacological Treatments ◽  
Disruptive Disorders

History of vascular reactivity models and their involvement in hypertension pathogenesis

VASA ◽  
2017 ◽  
Vol 46 (6) ◽  
pp. 431-439 ◽  
Author(s):  
Ana Gabriela Conceição-Vertamatti ◽  
Filipy Borghi ◽  
Fernando Canova ◽  
Dora Maria Grassi-Kassisse
Keyword(s):  
Blood Pressure ◽  
Adrenergic Receptors ◽  
Vascular Reactivity ◽  
Multifactorial Disease ◽  
Pharmacological Treatments ◽  
Beta Adrenergic Receptors ◽  
Vascular Area ◽  
History Of ◽  
Record Blood Pressure ◽  
Advance Knowledge

Abstract. Hypertension is a silent and multifactorial disease. Over two centuries ago, the first device to record blood pressure was developed, making it possible to determine normotension and to establish criteria for hypertension. Since then, several studies have contributed to advance knowledge in this area, promoting significant advances in pharmacological treatments and, as a result, increasing survival of hypertensive people. The main models developed for the study of hypertension and the main findings in the vascular area are included in this review. We considered aspects related to vascular reactivity, changes in the population, and action of beta adrenergic receptors in the pathogenesis of hypertension.

How to Psychologically Minimize Scratching Impulses

2014 ◽  
Vol 222 (3) ◽  
pp. 140-147 ◽  
Author(s):  
Ariane Sölle ◽  
Theresa Bartholomäus ◽  
Margitta Worm ◽  
Regine Klinger
Keyword(s):  
Cognitive Processes ◽  
Placebo Effect ◽  
Psychological Factors ◽  
Pharmacological Treatments ◽  
Physiological Basis ◽  
Psychological Mechanisms ◽  
Physical Complaints ◽  
Factors Influencing ◽  
The Impact ◽  
Placebo Model

Research in recent years, especially in the analgesic field, has intensively studied the placebo effect and its mechanisms. It has been shown that physical complaints can be efficiently reduced via learning and cognitive processes (conditioning and expectancies). However, despite evidence demonstrating a large variety of physiological similarities between pain and itch, the possible transfer of the analgesic placebo model to itch has not yet been widely discussed in research. This review therefore aims at highlighting potential transfers of placebo mechanisms to itch processes by demonstrating the therapeutic issues in pharmacological treatments for pruritus on a physiological basis and by discussing the impact of psychological mechanisms and psychological factors influencing itch sensations.

Seven-Year Follow-Up of Screening for Hypertension and Diabetes at a Dental Clinic

2019 ◽  
Author(s):  
Göran Friman
Keyword(s):  
Antihypertensive Drugs ◽  
Study Data ◽  
Initial Screening ◽  
Pharmacological Treatments ◽  
Medical Screening ◽  
Follow Up Study ◽  
Undiagnosed Hypertension ◽  
Dental Setting ◽  
Study Participants

Objective: To describe the distribution of risk, diagnosis and pharmacological treatments for diabetes and hypertension after seven years among patients provided with opportunistic medical screening in a dental setting. Material and Methods: The initial screening’s 170 participants were asked to take part in a seven-year follow-up study. Data were collected through self-reported information in a written health declaration. Outcome measures: • Number of study participants who had passed away • Prescription of antidiabetics or antihypertensives • Changes in weight and height to calculate body mass index (BMI) Results: The follow-up study consisted of 151 participants. Twenty had passed away. The risk needs for medicating with antihypertensive drugs after seven years for those not receiving pharmacological treatment at the initial screening was 3.7 times greater (p=0.025 CI 1.2-11.3) for participants with a diastolic blood pressure (BP) ≥ 90 mm Hg (85 for diabetics) than for the others. The risk was 3.9 times greater (p=0.020 CI 1.2-12.6) for those with a systolic BP of 140-159 mm Hg and 54.2 times greater (p<0.0001 CI 9.8-300.3) for those with a systolic BP ≥ 160 mm Hg than for those with a systolic BP 140 mm Hg. There were no changes in BMI. Conclusion: At least one in ten cases of incorrect medication or undiagnosed hypertension may be identifiable through opportunistic medical screening

Recent Advances in the Development of Broad-Spectrum Antiprotozoal Agents

2020 ◽  
Vol 27 ◽  
Author(s):  
Antonio Moreno-Herrera ◽  
Sandra Cortez-Maya ◽  
Virgilio Bocanegra-Garcia ◽  
Bimal Krishna Banik ◽  
Gildardo Rivera
Keyword(s):  
Giardia Lamblia ◽  
Heterocyclic Compounds ◽  
Trichomonas Vaginalis ◽  
Mechanisms Of Action ◽  
Parasitic Infections ◽  
Parasitic Diseases ◽  
Pharmacological Treatments ◽  
Preclinical Development ◽  
Leishmania Spp ◽  
Effective Drugs

: Infections caused by Trypanosoma brucei, Trypanosoma cruzi, Leishmania spp., Entamoeba histolytica, Giardia lamblia, Plasmodium spp., and Trichomonas vaginalis, are part of a large list of human parasitic diseases. Together, they cause more than 500 million infections per year. These protozoa parasites affect both low- and high-income countries and their pharmacological treatment is limited. Therefore, new and more effective drugs in preclinical development could improve overall therapy for parasitic infections even when their mechanisms of action are unknown. In this review, a number of heterocyclic compounds (diamidine, guanidine, quinoline, benzimidazole, thiazole, diazanaphthalene, and their derivatives) reported as antiprotozoal agents are discussed as options for developing new pharmacological treatments for parasitic diseases.

Conventional versus Mindfulness-based Interventions for Anxiety and Worry: A Review and Recommendations

2020 ◽  
Vol 16 (1) ◽  
pp. 60-67
Author(s):  
Deah Jo Abbott ◽  
Caleb Wayne Lack
Keyword(s):  
Treatment Options ◽  
Additional Treatment ◽  
Third Wave ◽  
Stage Model ◽  
Pharmacological Treatments ◽  
The Past ◽  
Behavioral Therapies ◽  
Cognitive Behavioral Therapies ◽  
Specific Disorders ◽  
Psychiatric Problems

Anxiety disorders are among the most prevalent and most functionally impairing psychiatric problems experienced by the population. Both pharmacological and psychological evidencebased treatments exist for a number of specific disorders, but may fail to fully relieve symptoms, pointing to the need for additional treatment options. Often considered to be part of the “third wave” of cognitive-behavioral therapies, treatments incorporating mindfulness have emerged in the past two decades as increasingly popular with clinicians and frequently sought out by consumers. The present article reviews the extant literature regarding the efficacy and effectiveness of mindfulnessbased treatments for anxiety, worry, and related problems. Although they have not attained the solid empirical status of CBT or certain pharmacological treatments, the extant research shows mindfulness- based interventions appear to be a promising and useful treatment for people suffering from anxiety and worry. Further work should be done, levels 3-5 of the NIH stage model to determine whether or not they should be further implemented.

Pharmacological treatments for chronic fatigue syndrome in adults

2014 ◽  
Author(s):  
Kelly Hard ◽  
Hugh E Rickards ◽  
Mohammed S Haque ◽  
Christopher Ward
Keyword(s):  
Chronic Fatigue Syndrome ◽  
Chronic Fatigue ◽  
Pharmacological Treatments ◽  
Fatigue Syndrome

scholarly journals Emerging Pharmacological Treatments for Cerebral Edema: Evidence from Clinical Studies

2020 ◽  
Vol 60 (1) ◽  
pp. 291-309 ◽  
Author(s):  
Jesse A. Stokum ◽  
Volodymyr Gerzanich ◽  
Kevin N. Sheth ◽  
W. Taylor Kimberly ◽  
J. Marc Simard
Keyword(s):  
Central Nervous System ◽  
Clinical Trials ◽  
Nervous System ◽  
Cerebral Edema ◽  
Clinical Studies ◽  
Central Nervous System Disease ◽  
Ancient Egypt ◽  
Nervous System Disease ◽  
Pharmacological Treatments ◽  
System Disease

Cerebral edema, a common and often fatal companion to most forms of acute central nervous system disease, has been recognized since the time of ancient Egypt. Unfortunately, our therapeutic armamentarium remains limited, in part due to historic limitations in our understanding of cerebral edema pathophysiology. Recent advancements have led to a number of clinical trials for novel therapeutics that could fundamentally alter the treatment of cerebral edema. In this review, we discuss these agents, their targets, and the data supporting their use, with a focus on agents that have progressed to clinical trials.

Sign in / Sign up

Export Citation Format

Share Document